FDA clears Phase III path for Lytix ruxotemitide
FDA cleared the Phase III development path for ruxotemitide in Lytix Biopharma’s program.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.